Replies to post #119569 on Biotech Values

[mcbio]

I keep telling myself, this thing is a buy under 8 bucks, but I fail to actually buy. And watching while that becomes true. 4th mouse gets the cheese?

IMHO, the market is pricing in hardly any chance of success for fostamatinib in Phase 3 and assigning very little value to the rest of RIGL's pipeline. We'll see if that ultimately proves to be a bit short-sighted. (I'm betting that it will though I haven't yet taken a position in RIGL again.)

[orangeone]

Rigl: Although i like rigl and have a few shares that i never bothered to sell, I'm somewhat wary of this. The PR states that the last event was a "series" of P1 trials starting in 1997...that's quite a while ago. Could this suggest that there were delivery issues such that doses suitable to moving on to a p2 were never found?

Also, a [very] cursory look back at the Pfe-Rigl agreement shows that pfe had the right to sublicense freely, yet they opted to terminate and return to rigl. If this project were so great, Pfe could have outlicensed it. Granted there were diligence obligations that Pfe may have been butting up against, but still, rigl pays nothing other than some royalties to pfe upon commercialisation.